Translational Platform

Accelerate Drug Discovery with an Integrated Translational Platform

WuXi Biology and Testing’s Translational Platform bridges discovery research and preclinical development through integrated pharmacology, biomarker, and translational research capabilities. Our multidisciplinary team supports informed decision-making with pharmacodynamic models, immune profiling, biomarker analysis, and bioassays that help evaluate therapeutic candidates across multiple modalities.

Our AAALAC-accredited facilities include more than 50,000 square feet of dedicated translational research laboratories and support studies in non-human primates, canine, and swine models. By integrating translational biology with bioanalysis and discovery services, we help clients generate meaningful data that accelerates candidate selection and de-risks drug development.

Comprehensive Biomarker Research and Tissue Banking

Our biomarker platform supports translational research with comprehensive tissue banking and molecular analysis capabilities.

  • Collection and banking of PBMCs, FFPE samples, fresh frozen tissues, microbiome samples, and other biospecimens
  • Samples available from non-human primates, canine, swine, rat and mouse studies
  • DNA, RNA, and protein biomarker analysis
  • Pharmacodynamic biomarker strategies to support target engagement and mechanism of action
  • Integrated biomarker support from discovery through preclinical development.

Preclinical Pharmacodynamic Models

Our translational pharmacology team develops clinically relevant pharmacodynamic models to evaluate therapeutic efficacy, target engagement, and immune responses across multiple disease areas.

Capabilities include:

  • Immune profiling
  • Patient-derived xenograft (PDX), cell-derived xenograft (CDX), humanized models and syngeneic tumor models
  • Ex vivo and in vivo immune-cell activation assays, etc.
  • Receptor occupancy and Target engagement assays
  • Translational studies supporting oncology, immunology, inflammation, rare diseases, neuroscience, metabolism, cardiovascular diseases, and other therapeutic area programs

Bioassay, Biosafety and Virus Testing

Our integrated analytical and biosafety capabilities support the development of biologics, and other emerging modalities.

Services include:

  • Bioanalytical assay development and validation
  • Bioassays for novel therapeutic modalities
  • Mycoplasma testing
  • Sterility testing
  • Endotoxin testing
  • Virus detection and characterization
  • Cell line and cell culture process testing
  • Immunogenicity assessment

Related Services

Our Translational Platform works seamlessly with WuXi Biology and Testing’s discovery and development capabilities to generate the data needed for confident decision-making throughout drug discovery and preclinical development.

Discovery Biology

Advance programs with integrated in vitro & in vivo biology services supporting target validation, efficacy, and mechanism of action studies.


Learn More

DMPK

Optimize candidate selection through integrated ADME, pharmacokinetics, metabolism, and PK/PD studies.


Learn More

Bioanalysis

Generate reliable pharmacokinetic, biomarker, and bioanalytical data with validated analytical methods.


Learn More

Safety Assessment

Reduce development risk with integrated toxicology, safety pharmacology, pathology, and regulatory support.


Learn More
Discuss Program

Discuss Your Program with Us

Share your development goals and key challenges with our experts to define the right path forward.

Discuss Your Program